On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

BrightGene Bio-Medical Technology Co., Ltd.

23 YRS

Jiangsu, China

CNY 410 Million

24642 m²

100-500 people

Main Products: Obeticholic Acid / Tebipenem Pivoxil / Laninamivir Octanoate / Dienogest / Carboprost Tromethamine / Fish Oil / Eldecalcitol / Oseltamivir Phosphate / Sugammadex / Pimecrolimus / Spinosyn D / Entecavir

Jiangsu, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

Obeticholic Acid / CAS 459789-99-2

OVERVIEW

Packaging

5 KG/BOTTLE

Lead Time

14-30 days

REQUEST A QUOTATION

Submit

Get Free Samples

Less than 1KG required

DESCRIPTION

Obeticholic Acid

Product introduction:

Obeticolic acid, also known as 6-ethyl chenodeoxycholic acid, is a new derivative of chenodeoxycholic acid (CDCA) in human primary bile acids. It is a natural ligand of farneside derivative X receptor (FXR). Obecholic acid is a farnesol X receptor agonist, which indirectly inhibits the gene expression of cytochrome 7a1 (CYP7A1) by activating farnesol X receptor. Because CYP7A1 is the rate limiting enzyme of cholic acid biosynthesis, OBE cholic acid can inhibit cholic acid synthesis and be used to treat primary biliary cirrhosis and nonalcoholic fatty liver disease.

CAS：459789-99-2

Molecular formula: C₂₆H₄₄O₄

Molecular weight: 420.63

Structural type:

Product purpose:

Studies have shown that insulin resistance plays an important role in the pathogenesis of NAFLD / NASH. Insulin sensitizers such as thiazolidinediones have been proved to be effective in improving liver inflammation and fat content, but they can not block the progression of fibrosis caused by Nash. Farneside derivative X receptor also improves insulin resistance and plays an important role in the metabolism of bile acids, lipids and sugars.

Typical Properties

Obicholic acid was developed by intercept pharmaceutical company in the United States. Its compound patent was applied in the United States in 2001 with the patent number of us7138390. At present, it has not applied for compound patent in China. Obecholic acid is the first drug developed for the treatment of cholestatic liver disease in 20 years. It is aimed at patients with insufficient response or intolerance to ursodeoxycholic acid.

CAS No.

459789-99-2

Formula

C26H44O4

Molecular Mass

420.62500

Exact Mass

420.32400

PSA

77.76000

Logp

5.11400

IUPAC

(4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

SMILES

CCC1C2CC(CC[C@@]2(C3CC[C@]4(C(C3C1O)CCC4C(C)CCC(=O)O)C)C)O

Matter Classification

organic

GET SAMPLE